文献速递消化道肿瘤与早癌消化内镜

使用组织系统病理学检测预测巴雷特食管进展:国际多中心研究的汇总分析

Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-22

该研究汇总多个国际研究的个体患者数据,评估在专家病理复核基础上增加组织系统病理学检测(TissueCypher)对巴雷特食管进展风险的附加预测价值。高风险的检测分类可独立预测进展为高级别异型增生/腺癌(OR 6.0,95%CI 2.9-12.0),含检测风险分类的模型预测能力优于不含者(全队列c统计量0.75 vs 0.68,P<.0001)。检测高风险分类的灵敏度38%、特异度94%。

要点

  • TissueCypher高风险分类独立预测巴雷特食管进展为高级别异型增生/腺癌,OR 6.0(95%CI 2.9-12.0)。
  • 含TissueCypher风险分类的模型预测优于不含者,全队列c统计量0.75 vs 0.68(P<.0001)。
  • 检测高风险分类灵敏度38%、特异度94%,特异度高但灵敏度中等。

核心结论

  • 客观的组织系统病理学检测高风险分类是巴雷特食管患者发生进展的强独立预测因子,较单纯临床变量显著改善进展风险预测。
  • 检测特异度高,但灵敏度中等。

研究设计与样本

  • 汇总多个国际研究的个体患者水平数据进行汇总分析。
  • 共分析552例患者,基线无异型增生472例、不确定异型增生32例、低级别异型增生48例,含152例进展者和400例未进展者。
  • 分析人口学、临床特征、TissueCypher风险分类/评分和进展状态,采用条件逻辑回归建立含与不含TissueCypher风险分类(低、中、高)的多变量进展预测模型,计算c统计量并用似然比检验比较。
  • 开发了整合临床变量和TissueCypher风险分类的风险预测计算器。

主要发现

  • 高风险检测分类独立预测进展为高级别异型增生/腺癌风险升高,OR 6.0(95%CI 2.9-12.0)。
  • 专家确认的低级别异型增生同样预测进展风险升高,OR 2.9(95%CI 1.2-7.2)。
  • 含TissueCypher风险分类的模型预测进展显著优于不含者:全队列c统计量0.75 vs 0.68(P<.0001)。
  • 非异型增生巴雷特食管亚组中,含TissueCypher风险分类的模型c统计量0.72 vs 0.63(P<.0001)。
  • TissueCypher高风险分类的灵敏度38%、特异度94%。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Prediction of progression risk in Barrett's esophagus (BE) may enable personalized management. We aimed to assess the adjunct value of a tissue systems pathology test (TissueCypher) performed on paraffin-embedded biopsy tissue, when added to expert pathology review in predicting incident progression, pooling individual patient-level data from multiple international studies METHODS: Demographics, clinical features, the TissueCypher risk class/score, and progression status were analyzed. Conditional logistical regression analysis was used to develop multivariable models predicting incident progression with and without the TissueCypher risk class (low, intermediate, high). Concordance (c-) statistics were calculated and compared with likelihood ratio tests to assess predictive ability of models. A risk prediction calculator integrating clinical variables and TissueCypher risk class was also developed. RESULTS: Data from 552 patients with baseline no (n = 472), indefinite (n = 32), or low-grade dysplasia (n = 48) (comprising 152 incident progressors and 400 non-progressors) were analyzed. A high-risk test class independently predicted increased risk of progression to high-grade dysplasia/adenocarcinoma (odds ratio, 6.0; 95% confidence interval, 2.9-12.0), along with expert confirmed low-grade dysplasia (odds ratio, 2.9; 95% confidence interval, 1.2-7.2). Model prediction of progression with the TissueCypher risk class incorporated was significantly superior than without, in the whole cohort (c-statistic 0.75 vs 0.68; P < .0001) and the nondysplastic BE subset (c-statistic 0.72 vs 0.63; P < .0001). Sensitivity and specificity of the high risk TissueCypher class were 38% and 94%, respectively. CONCLUSIONS: An objective tissue systems pathology test high-risk class is a strong independent predictor of incident progression in patients with BE, substantially improving progression risk prediction over clinical variables alone. Although test specificity was high, sensitivity was modest.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Iyer PG, Codipilly DC, Chandar AK, et al. Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies. Clin Gastroenterol Hepatol. 2022. PMID: 35217151. doi:10.1016/j.cgh.2022.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。